StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/303% below fair value
$33.79−0.71 (-2.06%)

Close on Nov 13, 2026Market cap $1.03BP/E –Yield 0.00%

Castle Biosciences profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Castle Biosciences's profit margin for the twelve months ending Sep 30, 2026 was -6.1%. For fiscal 2025 it was -7.0%, against 5.5% the year before. The highest annual figure on record is 10.2% in fiscal 2019.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-7.0%−12.5
FY2024Dec 31, 20245.5%+31.6
FY2023Dec 31, 2023-26.1%+22.8
FY2022Dec 31, 2022-49.0%−15.7
FY2021Dec 31, 2021-33.3%−16.8
FY2020Dec 31, 2020-16.4%−26.6
FY2019Dec 31, 201910.2%+38.1
FY2018Dec 31, 2018-27.9%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-4.0%−3.4
Q2 FY2026Jun 30, 2026-2.0%−7.2
Q1 FY2026Mar 31, 2026-17.4%+12.0
Q4 FY2025Dec 31, 2025-2.7%−13.8
Q3 FY2025Sep 30, 2025-0.6%−3.2
Q2 FY2025Jun 30, 20255.2%−5.0
Q1 FY2025Mar 31, 2025-29.4%−25.9
Q4 FY2024Dec 31, 202411.1%+15.0
Q3 FY2024Sep 30, 20242.6%+13.9
Q2 FY2024Jun 30, 202410.3%+47.7
Q1 FY2024Mar 31, 2024-3.5%+66.0
Q4 FY2023Dec 31, 2023-3.9%+49.9
Q3 FY2023Sep 30, 2023-11.2%+43.5
Q2 FY2023Jun 30, 2023-37.5%−32.7
Q1 FY2023Mar 31, 2023-69.5%+22.2
Q4 FY2022Dec 31, 2022-53.8%−28.1
Q3 FY2022Sep 30, 2022-54.7%−4.5
Q2 FY2022Jun 30, 2022-4.7%+33.9
Q1 FY2022Mar 31, 2022-91.7%−72.9
Q4 FY2021Dec 31, 2021-25.7%+2.6
Q3 FY2021Sep 30, 2021-50.2%−20.1
Q2 FY2021Jun 30, 2021-38.6%−27.8
Q1 FY2021Mar 31, 2021-18.8%−22.0
Q4 FY2020Dec 31, 2020-28.3%−39.9
Q3 FY2020Sep 30, 2020-30.2%−69.7
Q2 FY2020Jun 30, 2020-10.8%+1.0
Q1 FY2020Mar 31, 20203.3%+18.9
Q4 FY2019Dec 31, 201911.7%−22.2
Q3 FY2019Sep 30, 201939.6%+132.5
Q2 FY2019Jun 30, 2019-11.8%+67.5
Q1 FY2019Mar 31, 2019-15.6%+83.6
Q4 FY2018Dec 31, 201833.8%–
Q3 FY2018Sep 30, 2018-92.9%–
Q2 FY2018Jun 30, 2018-79.3%–
Q1 FY2018Mar 31, 2018-99.2%–

More Castle Biosciences figures

See a number that looks wrong?